Results Of 43 guidelines examined, 23 used CUA for specific interventions yielding 138 base-case incremental cost-effectiveness ratio (ICER) estimates, 11 used CUA for a threshold or 'what if' analysis, 1 used CEA, 3 used CCA, 1 used CBA and CUA and 1 used CEA and CUA, 5 did not require economic modelling. Compared with the earlier period, the median ICER for the 138 estimates was substantially higher (£7843 versus £1053) and there was greater variability (a higher proportion in the later period was cost-saving, but a higher proportion was also over £20 000 per quality adjusted life year).
Potential topics for NICE guidelines are first considered by the NICE topic oversight group, taking into account the existence of NICE-accredited guidance and the priority of the topic according to commissioners, professional organizations and service users. NICE then discusses identified topics with the Department of Health and Public Health England (for public health guidelines) and NHS England (for clinical guidelines) and a prioritized list is agreed. 6 NICE's approach to assessing the cost-effectiveness of public health interventions remains relatively unchanged, although the guidance on public health guideline development has been superseded by a unified guidelines manual. 6 This manual sets out the reference case for economic evaluation and advises on the use of economic evidence in guideline development. For interventions with costs and health outcomes in NHS settings, the reference case stipulates that the type of economic evaluation must be a cost-utility analysis (CUA). Despite much discussion in the literature, 7, 8 the 'threshold' below which interventions are generally considered to be cost-effective remains at £20 000 per quality adjusted life year (QALY). For interventions with health and non-health outcomes in public sector and other settings, the reference case additionally lists cost-effectiveness analysis (CEA), cost-consequences analysis (CCA) and cost-benefit analysis (CBA) as potential types of economic evaluation. 6 The budget available to Local Government would appear to be insufficient to accommodate all interventions identified as cost-effective.
This study updates the original analysis (Owen 2011) 1 for interventions where the incremental cost-effectiveness ratio (ICER) estimates were available. In addition, it aimed to explore the different types of economic evaluation used in NICE Public Health guidelines.
Methods
Economic evaluations undertaken for every NICE public health guideline published between 2011 and 2016 were examined. Each economic evaluation was categorized by type: CUA, CEA, CBA and CCA. It was noted that some guidelines may use more than one type of analysis. CUAs were further categorized by those with base-case estimates, and those that only used threshold or 'what if ' analysis, where the specific cost and/or effectiveness of an intervention is not known.
The NICE guideline manual states that the comparator for public health interventions should be 'interventions routinely delivered in the public sector, including those regarded as best practice.' 6 In practice, the evidence base for public health interventions is often limited, and trials that report 'best practice' as a comparator may have different interpretations of what this is. Furthermore, 'best practice' is not necessarily consistent across England since public health is funded at the local rather than national level. To compare an intervention against all possible comparators would require network meta-analyses which is frequently not possible because of a paucity of information and heterogeneity in the study population, comparators and outcomes. The economic evaluations considered in NICE public health guidelines and in this study are therefore pairwise comparisons between one intervention and comparator, usually based on a single study or meta-analysis. Each evaluation represents a specific case study and is not necessarily generalizable to all populations and settings, so for some guidelines there are multiple interventions which seem similar.
Cost-utility analyses
For interventions with base-case estimates, the analysis performed by Owen et al. (2011) 1 was repeated. The incremental cost-effective ratios (ICERs) reported for each intervention were extracted from the model reports and summarized by topic and according to one of five categories: cost-saving (costs less and produces more benefits than the comparator); between £0 and <£20 000 per QALY; between £20 000 and <£30 000 per QALY; £30 000 per QALY and above; and dominated (costs more and produces less benefit than the comparator). The number of ICERs that were cost-saving or dominated were counted. The median ICER for interventions in each of the remaining three categories was calculated. This approach provided consistency with the original paper and enabled an updated comprehensive list of the cost-effectiveness of public health interventions to be produced. The overall median was also calculated and compared with that of the earlier period. The findings from the updated analysis were compared with those from the 2011 analysis using comparisons between median ICERs and proportion of interventions cost-saving and cost-effective. The reasons for differences in results, and the implications of these were explored.
Other types of economic evaluation
We reviewed how guidelines were developed where specific CUA evidence of interventions was unavailable. We examined interventions where CEA, CCA and CBA have been used, to understand scenarios in which these types of economic evaluation are appropriate and how NICE committees consider this evidence in developing guidelines.
Results
Forty-three guidelines were published between the publication of Owen et al. (2011) 1 , and September 2016. Twentythree of these guidelines used CUA for specific interventions and provided 138 base-case ICER estimates. A further 11 guidelines used CUA only for a threshold or 'what if ' analysis. One guideline used a CEA, and three guidelines used CCA. One guideline used CBA in addition to CUA and one used CEA in addition to CUA. Five guidelines did not require economic modelling.
CUA base-case ICERs
The 2011-16 ICERs are compared to those from the original analysis (Owen 2012) 1 in Table 1 . The proportion of interventions which are cost-effective at £20 000/QALY has decreased from 85.5 to 63%, but the proportion which are cost-saving has increased. The proportion which are dominated has decreased, but the proportion which are not costeffective at £20 000/QALY or £30 000/QALY has increased. The median ICERs for interventions with ICERs ranging from £0 to £20 000/QALY, £20 000 to £30 000/ QALY and over £30 000/QALY have all increased. A summary of the ICERs by guideline is presented in Table 2 .
'What if' analysis
Eleven guidelines used CUA, but used a 'threshold' or 'what if ' scenario analysis framework alone and therefore do not report specific ICERs. This approach considers at what cost and effectiveness interventions would be cost-effective rather than calculating base-case ICERs for specific interventions. It is similar to a sensitivity analysis, but where there is no base-case ICER. It is used when the value of one or more of the parameters is unknown-several likely possible values of the parameters are chosen, and the costeffectiveness is worked out. The idea is to find out how big the effect or how low the cost would have to be for the intervention to be borderline cost-effective.
Cost-effectiveness analysis
One guideline covering contraceptive services for under 25s (PH51) used CEA, reporting outcomes in natural units (pregnancy or abortion averted). 9 The use of QALYs was not appropriate for this guideline because the interventions aimed to delay or prevent conception and NICE does not attempt to place a value on potential life in the future. The analysis considered several interventions, some of which resulted in net cost savings and which provided a clear economic case for recommending contraceptive services for young people.
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Cost-consequences analysis
Three guidelines used CCA alone, reporting the costs and outcomes for intervention and comparator without quantifying a comparison: NG44 for community engagement programmes 11 , NG48 for oral health promotion programmes in nursing homes 12 and PH56 for interventions to increase the uptake of vitamin D supplements. 13 In each case, this analysis was chosen because there was a lack of evidence linking the outcomes included in the effectiveness studies with health related quality of life, and there were other important dimensions to take into account.
Cost-benefit analysis
One guideline, for unintentional injuries on the road, used CBA, in addition to CUA. CBA was included because the interventions under consideration would be funded by the transport sector, whose preferred form of economic evaluation is CBA. 14 
Discussion
Main finding of this study
This study found that a smaller proportion of interventions were estimated to be cost-effective at £20 000/QALY in this analysis than in 2011. This should not be interpreted as public health interventions becoming less cost-effective, but more an indication of differences between the two time periods in the types of interventions and topic areas assessedthe topics that were chosen earlier may have been those that were (on average) more cost-effective. When we consider the broad remit of public health interventions that could be funded, we see that there is wide variation in their costeffectiveness. Decision makers need to be aware of this variation in order to maximize health gain within a limited budget. It is imperative that decision makers carefully consider the costs and benefits of public health interventions when making funding decisions.
Clinical interventions often have high incremental costs as a result of new technologies, whereas public health interventions tend to have incremental lower costs per person. This may be because the interventions are delivered on a population level and so the cost is shared between a large group and the benefit only applies to a few individual, or may be because the interventions have relatively low costs. With relatively low incremental costs and QALYs, the ICERs of public health interventions are very sensitive to small changes in intervention costs or THE COST-EFFECTIVENESS OF PUBLIC HEALTH INTERVENTIONS effectiveness, which is why seemingly similar interventions can have very different results. Decision makers and funders therefore need to carefully consider the costs and benefits of interventions they commission, either by comparing the interventions to those with published ICERs (such as these here) or by evaluating the new programme.
In June 2015, the Government announced a cut of £200 million in the 2015/16 public health grant to local authorities. Further cuts of £77 million and £84 million are planned for 2016/17 and 2017/18. 15 There is growing evidence that these significant financial pressures are leading local authorities to disinvest in highly cost-effective non-statutory public health services such as local stop smoking services. 16 The likely knock-on effect is that other public services, particularly the NHS, will experience increased pressure and higher costs, though this may not occur immediately or even within a couple of years of the reduction in services. Cost-effectiveness in public health optimizes over the long-term whereas commissioning cycles operate over very short time periods. The benefits of a healthy lifestyle may not be seen for decades, but will add many additional years to the lives of individuals and give higher health related quality of life. This raises a difficult but important question about the link between affordability and cost-effectiveness. Our current analysis found that nearly twothirds of the public health interventions studied in cost-utility analyses were cost-effective or cost-saving according at a threshold of £20 000 and as such provide excellent value for money. However, for Local Authorities with limited budgets, funding all these interventions may not be affordable. Research is needed to understand whether current disinvestment in non-statutory public health services reduces population net health benefit long-term.
The present analysis identified eleven guidelines informed by 'what if ' (or so-called 'threshold') analyses. Although not reported by Owen et al., there were only three guidelines in the time period up to 2011 that necessitated such an approach. This finding suggests that over time, NICE has received an increasing number of referrals for interventions and behaviours for which there are significant gaps in the evidence base. Threshold analyses are also useful where costs and effects vary widely between interventions and settings (but are known locally to decision makers).
We provide cases where methods other than CUA have been used. The decision to use the results of a CBA in transport-related interventions was justified, even though the conclusions from CUA were different due to a difference in perspective. The CUA took a public sector perspective and accounted for all QALYs and medical, police, local authority and department for transport costs invested or saved. The CBA was from a broader societal perspective and accounted for medical and human costs saved and lost output saved.
The role of CCA in developing recommendations is, arguably, less straightforward. When there is more than one outcome of interest, the relative importance of the outcomes is unclear and may differ from one person to another. There are other difficulties too, for example, the committee for community engagement found it difficult to make a general statement about whether community engagement provides good value for money based on the very specific and small number of case studies used in the analysis. However, others take the view that CCA is easier to understand for the purposes of decision making and resource allocation because decision makers are able to select the components most relevant to their perspective.
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What is already known on this topic
In 2012, Owen et al. estimated that most public health interventions considered in NICE guidelines were cost-effective. Others too have found that public health interventions are cost-effective, and that investing in prevention saves money in the future. 19 The challenges of economic modelling in public health are well known. 20 The suitability of the QALY outcome is widely discussed, and its limitations recognized. The role of other forms of economic analysis, in particular CCA is much debated, and its application in decision making warrants further investigation. 18, [21] [22] [23] What this study adds This paper provides an updated comprehensive source of the cost-effectiveness of public health interventions considered in NICE guidance and can be used by decision makers to inform funding decisions. While the general tenor of the results follows a similar path covered by the 2005-11 paper, the later results show a greater spread of the distribution of the ICERs, and quite a substantial increase in the overall median ICER. This leads into discussion about why ICERs vary, and the importance of decision makers carefully considering the costs and benefits of public health interventions. The use of CEA and CCA demonstrate the challenges that still remain in applying CUA analysis to the assessment of public health interventions. We hope that this contributes to wider discussions about the costeffectiveness of public health interventions generally, and the methods used for economic evaluation in public health.
Limitations of this study
Although this study represents a comprehensive list of the cost-effectiveness of public health interventions studied in NICE guidelines, it represents a subset of all public health interventions. This is because the interventions assessed by NICE are determined by a topic referral process which was described earlier, the number of topics that can be assessed by NICE is limited by the resources available, and the broad scope of public health makes for a substantial number of potential interventions. Table 2 shows that the topics referred to NICE between 2011 and 2016 covered a diverse range from interventions targeting individual lifestyle behaviours such as smoking, alcohol misuse and physical inactivity to those 'targeting' overall population well-being such as looked after children, cold homes and community engagement. We have been unable to carry out any form of regression analysis to isolate the determinants of cost-effectiveness because of the enormous range of possible determinants and the fragmentary nature of the cost-effectiveness analyses in the literature.
This study includes multiple similar interventions within several guidelines, such as those for smoking cessation in secondary care (PH48) and smoking harm reduction (PH45). Including multiple interventions with similar ICERs may have skewed the distribution of the data-in these examples all interventions have relatively low or dominant ICERs. In contrast, cold homes (NG6) and skin cancer prevention (PH32) have multiple interventions with very high ICERs. This is a feature of the availability of data to inform analyses for the guidelines and should be noted as a limitation. By calculating the median rather than the mean ICER we hoped to mitigate the impact of this skew.
It was not possible for us to compare the costeffectiveness of all NICE public health interventions in all guidelines, as not all include QALYs as an outcome. Even where QALYs were reported, care must be taken in making direct comparisons. It is likely that economic analyses will vary in the extent to which they have been able to fully capture the costs and consequences arising from complex, multi-faceted public health interventions.
A further limitation involves the comparator. In some cases, such as in smoking cessation, a number of interventions have in the past all been compared with a background quit rate ('doing nothing'), and most were cost-saving. A new intervention might well be cost-effective compared with no intervention, but may be dominated by an existing intervention. It is therefore imperative that decision makers ensure that they consider economic analysis that is similar to their decision problem in terms of population, intervention and comparator.
Finally, we note the limitation that adjustment for costs and standard of living adjustments for the real-money value of QALYs have not been made.
Conclusion
Although many public health interventions are cost-effective or even cost-saving, there is a large variation in the costeffectiveness of public health interventions, and some do not represent good value for money. In order to maximize health gain within a limited budget, it is imperative that decision makers and those funding public health understand the costs and benefits associated with different interventions.
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